India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Diamond Power Infrastructure: Growing Extra High Voltage and Data Center Segment

India’s Sugar Market: Record Prices, Shrinking Inventories And The Listed Beneficiaries

How Rising Coking Coal Prices Impacting Indian Steel Producers?

Mrs. Bectors Food: Premiumisation and Capacity Expansion FMCG Play

TD Power Systems: From Capacity Constraints to the Next Growth Phase

Jubilant Agri & Consumer Products: Turnaround in Polymer Business & Demerger Play

Lenskart: Growth Broadens, International Profitability Moves Into Double Digits

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Shilpa Medicare posted its highest-ever quarterly revenue of INR 465.78 crore in Q1FY27, up 45% YoY, with formulations revenue more than doubling.</li>
<li>The mix shift toward formulations and biologics, both structurally higher-margin than merchant APIs, is what is re-rating the stock, not the API business that built the company.</li>
<li>Segment-Level detail, a facility-by-facility capacity map, management's FY27/FY28 guidance and an honest look at the USFDA observation trail across Shilpa's plants.</li>
</ul>


Shilpa Medicare posted its highest-ever quarterly revenue of INR 465.78 crore in Q1FY27, up 45% YoY, with formulations revenue more than doubling.
The mix shift toward formulations and biologics, both structurally higher-margin than merchant APIs, is what is re-rating the stock, not the API business that built the company.
Segment-Level detail, a facility-by-facility capacity map, management's FY27/FY28 guidance and an honest look at the USFDA observation trail across Shilpa's plants.


Shilpa Medicare: Complex Formulations, CDMO and Biologics Drive the Next Phase